1. Modeling of Acute Pulmonary Arterial Hypertension in Pigs Using a Stable Thromboxane A2 Analogue (U46619): Dose Adjustment and Assessment of Hemodynamic Reactions
- Author
-
L Korobchenko, Lubov Mitrofanova, Olga Moiseeva, E Andreeva, Natalia Goncharova, H I Condori Leandro, L A Murashova, Evgeny N. Mikhaylov, A. D. Vakhrushev, S. E. Voronin, Michael M. Galagudza, and Y. A. Skorik
- Subjects
0301 basic medicine ,Cardiac function curve ,medicine.medical_specialty ,Thromboxane ,Hemodynamics ,General Biochemistry, Genetics and Molecular Biology ,03 medical and health sciences ,Thromboxane A2 ,chemistry.chemical_compound ,0302 clinical medicine ,Dose adjustment ,Internal medicine ,Vascular collapse ,medicine ,business.industry ,General Medicine ,medicine.disease ,Pulmonary hypertension ,030104 developmental biology ,Target level ,chemistry ,cardiovascular system ,Cardiology ,lipids (amino acids, peptides, and proteins) ,business ,030217 neurology & neurosurgery - Abstract
U46619, a synthetic analogue of thromboxane A2 was used for modeling acute stable and reversible pulmonary arterial hypertension. Administration of U46619 in high doses led to vascular collapse and inhibition of cardiac function. The doses of U46619 were empirically selected that allow attaining the target level of pulmonary hypertension without systemic hemodynamic disturbances. The possibility of attaining the target level of pulmonary hypertension and reversibility of changes after termination of U46619 infusion make this model attractive for evaluation of the efficiency of different therapeutic methods of treatment of pulmonary hypertension in large animals.
- Published
- 2021
- Full Text
- View/download PDF